Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Huaqiang Ouyang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7702-2545; OpenAlex author ID A5038071688, A5112159329. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers

Papers 8

  1. Systemic Chemotherapy With or Without Hepatic Arterial Infusion Chemotherapy for Liver Metastases From Pancreatic Cancer: A Propensity Score Matching Analysis. Co-author DOI 10.1016/j.clcc.2022.10.007↗
  2. Is lung involvement a favorable prognostic factor for pancreatic ductal adenocarcinoma with synchronous liver metastases?-A propensity score analysis. Co-author DOI 10.1080/17474124.2023.2183497↗
  3. Systemic chemotherapy in combination with liver-directed therapy improves survival in patients with pancreatic adenocarcinoma and synchronous liver metastases. Co-author DOI 10.1016/j.pan.2018.09.015↗
  4. Factors influencing survival of patients with pancreatic adenocarcinoma and synchronous liver metastases receiving palliative care. Co-author DOI 10.1016/j.pan.2017.07.002↗
  5. [Multidisciplinary treatment and survival analysis for 497 cases of pancreatic cancer with liver metastases]. Co-author DOI 10.3760/cma.j.issn.0376-2491.2016.06.003↗
  6. [A Retrospective Study of Chinese Herbal Medicine Combined with Systemic Chemotherapy and/or Regional Arterial Perfusion for Pancreatic Cancer with Liver Metas… Co-author DOI 10.7661/cjim.2015.06.0654↗
  7. Targeting cancer-related inflammation: Chinese herbal medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0070334↗
  8. Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine. Co-author DOI 10.1097/mpa.0b013e3181e6e398↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weidong Ma · 4 shared papers, 2017–2023 · strength 0.56
  2. Anna Sandström Gerdtsson · 2 shared papers, 2023 · strength 0.40
  3. Donglin Liu · 2 shared papers, 2023 · strength 0.40
  4. Zhanyu Pan · 3 shared papers, 2017–2023 · strength 0.38
  5. Manman Quan · 3 shared papers, 2016–2018 · strength 0.23
  6. Zhuchen Yan · 1 shared paper, 2023 · strength 0.18
  7. Ping Chen · 1 shared paper, 2023 · strength 0.18
  8. Tongguo Si · 1 shared paper, 2023 · strength 0.18
  9. Luming Liu · 2 shared papers, 2011–2013 · strength 0.07
  10. Zhu-chen Yan · 1 shared paper, 2015 · strength 0.06
  11. Juan Zhang · 1 shared paper, 2013 · strength 0.04
  12. Peng Wang · 1 shared paper, 2013 · strength 0.04
  13. Zhen Chen · 1 shared paper, 2011 · strength 0.03
  14. Zhiqiang Meng · 1 shared paper, 2011 · strength 0.03
  15. Peng Wang · 1 shared paper, 2011 · strength 0.03
  16. Lorenzo G. Cohen · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.